Keyphrases
Tumor
73%
Head-and-neck Cancer
63%
Phosphoinositide 3-kinase (PI3K)
53%
Interleukin-1β
50%
Tumor Cells
43%
Tumor Microenvironment
41%
Breast Cancer
36%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
32%
Mammalian Target of Rapamycin (mTOR)
30%
In Cancer
27%
Programmed Death-ligand 1 (PD-L1)
24%
PI3K Inhibitor
23%
N719
22%
Patient-derived Xenograft
22%
Cancer Cells
19%
Epidermal Growth Factor Receptor
18%
Metastasis
17%
Ovarian Cancer
17%
Acquired Resistance
16%
Microenvironment
15%
Oncogenesis
15%
Antitumor Efficacy
14%
HER3
14%
BKM120
14%
Synergize
14%
Glioblastoma
14%
Anti-PD-1 Therapy
14%
PIK3CA
14%
Trametinib
14%
Cancer Treatment
14%
Inflammation
13%
Cetuximab
13%
High-risk Human Papillomavirus (HR-HPV)
12%
Phosphatidylinositol 3-kinase Inhibitor
12%
Triple-negative Breast Cancer
12%
Antitumor Activity
12%
Gene Expression
12%
Tumor Tissue
11%
Lung Metastasis
11%
Homologous Recombination Repair
11%
PIK3CA mutation
11%
Estrogen Receptor
11%
Tumor-host Interactions
11%
Therapeutic Combinations
10%
Autophagy
10%
PARP Inhibitor (PARPi)
10%
Cancer Progression
10%
Tumor Invasiveness
10%
Cellular Pathways
10%
Cancer Therapy
10%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Malignant Neoplasm
63%
Head and Neck Cancer
59%
Head and Neck Squamous Cell Carcinoma
35%
Tumor Microenvironment
22%
Epidermal Growth Factor Receptor
21%
Immunotherapy
19%
Mouse
17%
Glioblastoma
15%
Alpelisib
14%
Buparlisib
14%
Cetuximab
13%
Lung Cancer
13%
Breast Cancer
13%
Immune Checkpoint Inhibitor
12%
Chemotherapy
12%
Carcinogenesis
11%
Receptor
11%
Triple Negative Breast Cancer
11%
Nanoparticle
11%
Programmed Death 1 Ligand 1
10%
Antitumor Activity
10%
Small Interfering RNA
10%
Biological Marker
10%
Disease
10%
Phosphatidylinositol 3 Kinase Inhibitor
10%
Epidermal Growth Factor Receptor 3
9%
Gamma Urogastrone
9%
Ovary Cancer
9%
Hydroxychloroquine
9%
Pembrolizumab
9%
Anticarcinogen
9%
Phosphotransferase
9%
Somatomedin
9%
Human Papillomavirus
8%
Tumor Growth
8%
Phosphatidylinositol 3 Kinase
8%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
8%
Cancer Growth
7%
Mouse Model
7%
Trametinib
7%
Tipifarnib
7%
CD8 Antigen
7%
Taselisib
7%
Monotherapy
6%
Cancer Model
6%
Protein Tyrosine Kinase
6%
Metastasis
6%
Phosphatidylinositol 3,4,5 Trisphosphate
5%
Lung Metastasis
5%
Medicine and Dentistry
Neoplasm
72%
Head and Neck Cancer
50%
Malignant Neoplasm
25%
In Vitro
24%
Tumor Microenvironment
24%
Head and Neck Squamous Cell Carcinoma
24%
Epidermal Growth Factor Receptor
20%
Immunotherapy
19%
Xenograft
18%
Tumor Cell
17%
Cancer Cell
17%
Metastatic Carcinoma
16%
Ovarian Cancer
15%
Breast Cancer
15%
Cancer Therapy
15%
Tumor Progression
15%
Fibroblast
14%
Glioblastoma
14%
Alpelisib
13%
Phosphoinositide 3-Kinase
13%
Trametinib
13%
Lung Cancer
12%
Homologous Recombination
11%
Recombination Repair
11%
Disease
11%
Phosphoinositide 3-Kinase Inhibitor
10%
Somatomedin
9%
Epidermal Growth Factor Receptor 3
9%
Interleukin 1
9%
Buparlisib
9%
Clinical Oncology
9%
Gamma Urogastrone
9%
Triple Negative Breast Cancer
9%
Pembrolizumab
9%
Carcinogenesis
9%
Antineoplastic Activity
8%
Cetuximab
8%
PARP Inhibitor
8%
Gene Expression
8%
Cancer Growth
8%
Wart Virus
7%
Receptor
7%
Ex Vivo
7%
Parathyroid Adenoma
7%
Immune Checkpoint Inhibitor
7%
Oncogene
7%
Radiation Therapy
7%
Cancer
6%
Monotherapy
6%
Programmed Cell Death
6%